Based on the available information, there is no evidence of any pending patents for a ready-to-use version of Nicardipine, a calcium channel blocker used to treat hypertension.

The first source, a drug patent watch website, does not list any pending patents for Nicardipine in its tradename version [1]. The other two sources are FDA documents for Nicardipine Hydrochloride, which is a version of Nicardipine that is already in use. One is a labeling supplement [2] and the other is an original new drug application [3]. These documents do not mention any pending patents for a ready-to-use version of Nicardipine.

However, it is important to note that this information is accurate as of the time of this response and the patent status can change. For the most up-to-date information, it is recommended to conduct a thorough patent search or consult with a patent attorney.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/NICARDIPINE
[2] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/022276Orig1s008.pdf
[3] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/019734Orig1s013.pdf